Best Drug Delivery Companies in California, United States
The 112 best Drug Delivery companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Halozyme.
Ranked: Best Drug Delivery companies in California
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Developer of drug delivery technologies for the treatment of various diseases | $1.3B | 46 mo ago | 373 373 → 536 (+44%) | Helen Torley CEO & President | Public | 715 patents Enabling subcutaneous delivery of biologics via hyaluronidase and advanced injector devices | 1 partnership |
| 2 | ReCode Therapeutics Developer of precision medicines for treating lung related diseases 67Funding top 17%Talent top 28%Moat top 31%Market top 42% All 7 signals ▾Fundingtop 17% Talenttop 28% Moattop 31% Markettop 42% Newstop 45% Techtop 48% Globalbottom 39% Funding: Raised $342M across 7 rounds · 7 rounds over 7 yrs (1.0/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 67/100 | $342M | 8 mo ago | 105 | Daniel Siegwart Co-Founder | Series B | — | — |
| 3 | Neurelis Therapeutics for CNS disorders | $221M | 45 mo ago | 2 | Craig Chambliss CEO and Co-founder | Series D | 55 patents Rapid CNS drug delivery formulations for seizures and psychosis (intranasal, oral film). | 2 awards |
| 4 | Zosano Pharma Developer of transdermal drug delivery systems for a broad range of therapeutic indications | $147M | 92 mo ago | 40 | — | Deadpooled | — | — |
| 5 | Biora Therapeutics Developer of smart pills for targeted drug delivery to treat gastrointestinal diseases | $117M | 30 mo ago | 54 | Adi Mohanty CEO | Public | — | — |
| 6 | Credence MedSystems Developer of smart devices for drug delivery | $100M | 18 mo ago | 20 20 → 13 (-35%) | Dan Thayer Co-Founder | Series D | 262 patents Safety-engineered syringes and multi-site micro-dose injection devices. | — |
| 7 | Alexza Developer of products for the treatment of acute and intermittent conditions | $97M | 123 mo ago | 72 | — | Public | — | — |
| 8 | Elucida Oncology Developer of a particle delivery platform using nanotechnology | $82M | 65 mo ago | 23 | — | Series B | 29 patents Targeted folate‑receptor nanoparticle drug delivery systems for oncology therapeutics. | — |
| 9 | Intersect ENT Developer of drug releasing implant to treat sinusitis | $77M | 73 mo ago | 371 | — | Acquired | — | — |
| 10 | Bionaut Labs Developer of miniature robots for drug delivery | $63M | 42 mo ago | 50 | Alex Shpunt Co-Founder | Series B | 76 patents Patents concentrated in health & consumer products | — |
| 11 | Shasqi Developer of local drug activation technology for tumors | $60M | 21 mo ago | 8 | — | Series B | 5 patents Bioorthogonal chemical reagents for selective in‑vivo labeling and drug delivery | 1 job opening · 1 launch |
| 12 | Genedit Developer of drug delivery system for genetic medicines 53Funding top 28%Talent top 28%Product top 30%Patents top 31% All 9 signals ▾Fundingtop 28% Talenttop 28% Producttop 30% Patentstop 31% Innovationtop 34% Moattop 36% Marketbottom 41% Techbottom 40% Globalbottom 40% Funding: Raised $58.5M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 53/100 | $58M | 19 mo ago | 39 39 → 64 (+64%) | — | Series B | 73 patents Non‑viral cationic polymers for biomolecule delivery and engineered Cpf1 guide RNAs | — |
| 13 | MannKind Corp Developer of small-molecule drugs | $50M | 63 mo ago | 322 | Michael Castagna Chief Executive Officer | Public | 1,985 patents Dry powder inhaler devices and pulmonary drug formulation/composition technologies. | 1 internship · 1 award |
| 14 | Renovis Pioneering drug discovery and development, accelerating concept to cure | $45M | 145 mo ago | 368 | — | Acquired | 191 patents Design of heterocyclic small‑molecule P2X7 modulators for neuro‑inflammatory therapies | — |
| 15 | Mantra Bio Developer of exosomes to deliver safe, highly targeted medicines | $44M | 41 mo ago | 17 | Terry Gaige Co-Founder And Vp Automation | Series A | — | — |
| 16 | Mercator MedSystems Developer of catheter-guided microfluid injection systems | $32M | 15 mo ago | 19 | Kirk Seward Founder | Series D | 105 patents Localized perivascular drug delivery devices for vascular disease treatment and prevention | — |
| 17 | Hallux Provider of subungual drug delivery technology for onychomycosis | $27M | 37 mo ago | 4 | Mark Taylor Co-Founder & CEO | Series B | 34 patents Topical antifungal nail (onychomycosis) treatment formulations and delivery methods. | — |
| 18 | Advanced NanoTherapies Developer of a drug delivery device for cardiac vascular diseases | $26M | 34 mo ago | 10 | Mehdi Shishehbor Co-Founder | Series A | — | — |
| 19 | Cellics Developing therapies for infectious diseases & autoimmune disorders using Nanosponge technology | $26M | 68 mo ago | 18 18 → 21 (+17%) | Lili Xie Co-Founder & Director | Series B | — | — |
| 20 | Corsair Phama Developer of drugs for the treatemnt of cardiac diseases | $23M | 33 mo ago | 5 | Bobby Singh Chief Executive Officer | Series B | — | — |
| 21 | Optimum Linking academic discoveries to clinical treatments for maximum cancer research benefits | $19M | 150 mo ago | — | Robert Marder Co-Founder | Funding Raised | 10 patents Patents concentrated in electrical & electronics | — |
| 22 | NeOnc Technologies Developer of drug delivery methods for pharma-based therapeutics | $19M | 10 mo ago | 4 | — | Public | 48 patents Monoterpene-derived anticancer drug formulations, especially perillyl alcohol derivatives. | — |
| 23 | Nano Precision Medical Implantable biopharmaceutical technology company improving chronic disease treatment and patient adherence | $15M | 123 mo ago | 35 | — | Acquired | — | — |
| 24 | Miist Therapeutics Developer of inhaled therapies for rapid symptom relief | $13M | 16 mo ago | — | Dalton Signor Founder & CEO | Series A | — | — |
| 25 | RenovoRx Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs | $11M | 3 mo ago | 6 | — | Public | 18 patents Targeted intravascular drug delivery via vasa vasorum for cancer and pancreatic therapies | — |
| 26 | NaNotics Developer of nanomedical platform for treating major human and animal diseases 32Moat top 25%Patents top 33%Funding top 38%Talent top 38% All 7 signals ▾Moattop 25% Patentstop 33% Fundingtop 38% Talenttop 38% Innovationtop 44% Globalbottom 43% Marketbottom 23% Moat: Editorial + unicorn rating 7/10 · IP moat: 59 patents Patents: 59 patents matched (strict assignee match) · 26 filings since 2022 vs 33 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $10M | 10 mo ago | 9 | John Dodgson Co-Founder & CTO | Series A | 59 patents Therapeutic biomolecule inhibition and nucleic‑acid‑based scavenger particle platforms | — |
| 27 | Cure Pharmaceutical Developer of oral thin film based drug delivery systems | $10M | 67 mo ago | 28 | Rob Davidson CEO Cure | Public | — | — |
| 28 | Arrogene Developer of cancer therapeutics based on a nanotechnological targeting platform | $9M | 79 mo ago | — | Larry Couture Chief Executive Officer | Deadpooled | 5 patents Polymeric drug delivery systems and antisense glioma therapeutics using polymalic acid. | — |
| 29 | Vivani Developer of a drug delivery medical device for diabetes | $8M | 14 mo ago | 37 37 → 36 (-3%) | Adam Mendelsohn Co-Founder & CEO | Public | — | 2 launchs |
| 30 | Cello Therapeutics Developer of cell membrane-coated nanoparticles for cancer drug delivery | $7M | 46 mo ago | 9 | Jie Zhang Chief Executive Officer | Series A | — | — |
| 31 | Hospi Corporation A catheter for rectal administration of medications | $7M | 72 mo ago | 10 10 → 20 (+100%) | Igal Ladabaum Co-Founder & CEO | Series A | — | — |
| 32 | MediPrint Developer of technology for ocular drug delivery | $7M | 51 mo ago | 8 | Praful Doshi CTO | Series A | 4 patents Custom 3D‑printed patient‑specific anatomical models, medical inserts, and fastening designs | — |
| 33 | Curaseal Minimally invasive drug delivery technologies for long-term treatment | $6M | 102 mo ago | 5 | Akshay Mavani CEO & Co-Founder | Seed | 55 patents Medical devices for vacuum‑assisted and inflatable treatment of enteric fistulas | — |
| 34 | Redwood Scientific Over-the-counter drugs that features oral strip delivery technology | $6M | 37 mo ago | 15 | Jason Cardiff President and CEO | Late Stage | — | — |
| 35 | Miist Therapeutics Developer of advanced inhalation drug delivery system | $6M | 21 mo ago | 4 | — | Series A | — | — |
| 36 | NOD Pharmaceuticals Developing drug delivery technology for oral drugs | $6M | 233 mo ago | — | William Lee CEO & Founder | Series B | — | — |
| 37 | TherOptix Developer of contact lenses for delivery of drugs | $5M | 36 mo ago | 6 | — | Funding Raised | — | — |
| 38 | AscentX Medical Regenerative medicine company focused on advanced tissue engineering and CMO services | $5M | 34 mo ago | 3 | — | Series A | — | — |
| 39 | Medipacs Infusion pumps for drug delivery | $4M | 140 mo ago | 2 | Mark Banister Founder | Seed | 45 patents Advanced polymer hydrogels and micro‑actuators for precise therapeutic fluid delivery | — |
| 40 | Ichor Medical Systems Provider of electroporation technology for the delivery of DNA drugs and vaccines | $3M | 189 mo ago | 13 | Bob Bernard CEO | Funding Raised | — | — |
| 41 | Signature Therapeutics Develops prodrug formulations that can prevent the misuse of prescription medications | $2M | 47 mo ago | 5 | Steven Shafer Co-Founder | Acquired | — | — |
| 42 | Handa Pharmaceuticals Specialty pharmaceutical company developing and commercializing high-quality prescription medications | $2M | 206 mo ago | 9 | Bill Liu President and CEO | Seed | — | — |
| 43 | Spinnaker Biosciences Drugs for the treatment of ocular diseases and cancer using its proprietary Nanoporous silicon particles… | $2M | 18 mo ago | 6 | — | Seed | — | — |
| 44 | Ovensa Canadian, early-stage biotech developing chitosan-based nanotech drug delivery for Oncology… | $1M | 105 mo ago | 3 | — | Seed | — | — |
| 45 | Delpor Developing once-yearly therapies for chronic diseases, focusing on CNS conditions | $1M | 80 mo ago | 12 | Tassos Nicolaou President & CEO | Series A | 76 patents Implantable sustained‑release drug delivery devices for small‑molecule therapeutics | — |
| 46 | Arcturus Therapeutics Developer of RNAi technologies for the treatment of rare orphan diseases | $1M | 32 mo ago | 337 | — | Public | 488 patents Lipid nanoparticle formulations for RNA/mRNA delivery and vaccine therapeutics | 1 partnership |
| 47 | Pharmaco-Kinesis Corporation Implantable infusion pump for drug delivery | $1M | 197 mo ago | 2 | Josh Shachar Founder & Inventor | Seed | 95 patents Implantable targeted drug delivery pumps and nanobiosensor platforms for brain tumor therapy and diagnostics | — |
| 48 | NAVAN Technologies Provider of therapeutic solution for gene therapy | $750K | 85 mo ago | 6 | Ryan Swoboda Co-Founder & CEO | Seed | 28 patents AI model orchestration platform for prompt engineering, virtual ID auth, and API parallelization | — |
| 49 | General Nanotherapeutics Developer of nanoparticles for long-term remission of immune-mediated disorders | $300K | 47 mo ago | — | David Horwitz CEO | Funding Raised | 6 patents Targeted nanomedicine formulations for treating immune-mediated diseases | — |
| 50 | Cellular Vehicles Developer of process automation tools for cell-based therapy manufacturing | $295K | 24 mo ago | 7 | — | Funding Raised | 11 patents Cellular therapy infusion systems and microfluidic devices for preparing and delivering cell suspensions | — |
Top 12 Drug Delivery companies in California
#1
Series B · Menlo Park, California · founded 2015 · 105 employees$342Mraised▾
Developer of precision medicines for treating lung-related diseases. The pipeline includes lead programs which includes RCT1100 an inhaled mRNA-based investigational therapy for primary ciliary dyskinesia caused by mutations in the DNAI1 gene and RCT2100 is an inhaled mRNA-based investigational therapy for cystic fibrosis. It has proprietary non-viral lipid nanoparticle platform that enables the delivery of a variety of payloads, and organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
- Sep 2025Series B$29M
- Sep 2023Series B$50M
- Jan 2023Series B$10M
- Jun 2022Series B$120M
#2
Public · Los Altos, California · founded 2009 · 6 employees$10.9Mraised▾
Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs. It develops endovascular catheters for the visceral and peripheral vascular systems. The RenovoRx device can be used to deliver both therapeutic(such as drugs)and diagnostic fluids(such as contrast agents) to the target organ through veins. The device allows for isolated vessel perfusion i.e. a balloon is inflated within the blood vessels to block blood flow to other organs to maximize the amount of blood flow(and IV fluids reaching the target organ.
- Mar 2026Post IPO$10M
- Apr 2024Post IPO$11.1M
- Jan 2024Post IPO—
- May 2018Series D$7M
#3
Public · Los Angeles, California · founded 2008 · 4 employees$18.7Mraised▾
Developer of drug delivery methods for pharma-based therapeutics. The company develops intranasal inhalation of perillyl alcohol for the treatment of malignant brain cancer (gliomas). The company has secured worldwide rights to NEO100, a purified version of perillyl alcohol, and has obtained approval from the FDA to perform clinical trials in patients with recurrent Grade 4 glioma.
- Aug 2025Grant (prize money)$2.5M
- Jul 2024Series A$18.3M
- Feb 2022Seed$50K
- Feb 2013Seed$24.8K
#4
Series D · Menlo Park, California · founded 2011 · 20 employees$99.9Mraised▾
Credence Medsystems manufactures and sells drug delivery technologies and prefilled pharmaceuticals. Its product portfolio includes Companion staked needle syringe, companion Luer syringe, companion dual chamber reconstitution safety syringe systems.
- Dec 2024Series D$12.7M
- Sep 2021Series D$39.9M
- Jan 2021Series C—
- Nov 2020Series C$15.4M
#5
Series D · San Leandro, California · founded 2000 · 19 employees$31.8Mraised▾
Developer of catheter-guided microfluid injection systems. The company offers micro-infusion catheters, which are designed to inject therapeutic agents directly and non-systemically through blood vessel walls into deep tissues. The company’s products are used in various therapies, such as treatments for plaque stabilization in diseased vessels, anti-tumour drugs, growth factors to stimulate cell division, and stem cell transplantation and gene therapies. Its technology also enables the commercialization of novel therapeutics for other vascular diseases, hypertension, oncology, and regenerative medicine.
- Mar 2025Grant (prize money)$4M
- Jun 2019Series D$14.3M
- Jun 2018Series D$11M
- Jun 2013Series B$6.5M
#6
Series A · Mill Valley, California · founded 2015 · 9 employees$10Mraised▾
Developer of nanomedical platform for treating major human and animal diseases. Its products remove the molecular signals or signal inhibitors that assist disease progression and are later cleared from the body via phagocytosis. It has features including nanoparticles made of biocompatible materials, the inclusion of a binding-capture agent, and the shielding of the capture agent with cell membrane receptors.
- Aug 2025Grant (prize money)$2M
- Oct 2023Series A—
- Series A$10M
#7
Series B · Berkeley, California · founded 2016 · 39 employees$58.5Mraised▾
Developer of drug delivery system for genetic medicines. The company has developed a NanoGalaxy platform that contains non-viral, non-lipid, polymer nanoparticles to deliver genetic medicines to the needed tissue to treat disease.
- Nov 2024Series B$35M
- Jan 2024Series A$24M
- Sep 2021Series A$26M
- Feb 2019Grant (prize money)$225K
#8
Series B · San Francisco, California · founded 2015 · 8 employees$60Mraised▾
Developer of local drug activation technology for tumors. The technology consists of a gel that contains activating agents that are inert in the body and a pro-drug modified with trans C compound. The gel will get inserted at the tumor site, pro-drug will get concentrated around the tumor and gel where interaction between the TransC compound and gel leads to the release of the active pro-drug at the tumor site.
- Sep 2024Grant (prize money)$1.6M
- Sep 2023Grant (prize money)$2M
- Dec 2021Grant (prize money)$1.9M
- Nov 2021Series B$50M
#9
Series A · Alameda, California · founded 2022$13.4Mraised▾
Developer of inhaled therapies for rapid symptom relief. The company utilizes a proprietary inhaler technology to deliver medication directly to the peripheral lung, enabling faster absorption into the bloodstream than traditional methods. This approach is being applied to develop treatments for various conditions, focusing on those with acute symptom onset where rapid action is critical. The platform features a small particle size for efficient delivery and a sterile, heat-free production process. Current development programs include treatments for smoking cessation and migraine.
- Feb 2025Series A$7M
- Aug 2024Series A$6.3M
- Oct 2022Seed$75K
#10
Public · San Diego, California · founded 1999 · 373 employees$1.3Braised▾
Developer of drug delivery technologies for the treatment of various diseases. The company's lead product is ENHANZE drug delivery technology, based on the proprietary enzyme rHuPH20, which is used to facilitate the delivery of injected drugs and fluids. Also, it offers Hylenex recombinant an endoglycosidase indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.
- Aug 2022Post IPO$625M
- Nov 2019Post IPO$388.5M
- Jan 2016Venture Debt$150M
- Jan 2014Venture Debt$20M
#11
Public · Emeryville, California · founded 2009 · 37 employees$8.2Mraised▾
Developer of a drug delivery medical device for diabetes. It offers a lead candidate NPM-119 a GLP-1 receptor agonist which is a subdermal, exenatide drug implant to treat type 2 diabetes. It is based on NanoPortal platform technology which make extended-release therapeutic implants.
- Mar 2025Post IPO$8.2M
#12
Public · San Diego, California · founded 2010 · 54 employees$116.6Mraised▾
Developer of smart pills for targeted drug delivery to treat gastrointestinal diseases. The company uses an ingestible smart capsule for the targeted delivery of therapeutics in the gastrointestinal tract to improve the treatment of Inflammatory bowel diseases. It develops pipelines for ulcerative colitis, diabetes, and autoimmune diseases.
- Dec 2023Post IPO$16.7M
- Apr 2020Series C$10M
- Nov 2019Series C$31.1M
- Oct 2017Series C$50M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery in California is moving
A read on the academic research around Drug Discovery in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 800 papers.
UCSF, UCSD, and UCLA optimistically drive California's drug discovery research, dominated by computational methods and protein dynamics, with breakthroughs surging markedly post-2020.
- University of California, San Francisco145
- University of California San Diego132
- University of California, Los Angeles92
- University of California, Davis65
- University of California, Berkeley63
- Computational biology19→97
- Chemical space3→36
- Small molecule7→30
- Virtual screening3→22
- Combinatorial chemistry2→20
- Computational biology12→47
- Docking (animal)7→21
- Bioinformatics1→13
- Pharmacology2→13
- Drug development1→10
- Chemical space1→6
- Drug repositioning1→4
- Virtual screening2→5
- Identification (biology)1→4
- Disease3→5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.